Specimatch Launches Service for Cancer Patients

In year two of the trial, Elevidys demonstrated statistically significant and clinically improvements across three key functional outcomes.

Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.

Being evaluated for the treatment of metastatic colorectal cancer, the combination regimen achieved an objective response rate of 61% compared to 40% for investigator’s choice of chemotherapy.

The top five episodes of our podcast in the year 2024, highlighted.

Extended collaboration will further explore the capabilities of Medidata Platform from early-phase trials to post-marketing surveillance.

Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve statistical significance for overall survival in patients with advanced HER2-negative gastroesophageal adenocarcinoma.